https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 AAPM medical physics practice guideline 13.a: HDR brachytherapy, part A https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50486 Wed 26 Jul 2023 19:04:21 AEST ]]> Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47094 Wed 14 Dec 2022 09:37:30 AEDT ]]> Technology assessment and quality improvement in a clinical HDR brachytherapy setting https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15944 Wed 11 Apr 2018 14:57:32 AEST ]]> Brachytherapy treatment for equine ocular and/or periocular squamous cell carcinoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22359 Wed 11 Apr 2018 12:52:26 AEST ]]> Accumulation of rectum dose-volume metrics for prostate external beam radiotherapy combined with brachytherapy: evaluating deformably registered dose distribution addition using parameter-based addition https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34511 0.1cc, D1cc, D2cc and D10cc were calculated in two ways. (i) Parameter-adding: the EBRT DVH parameters (or the EBRT prescription dose) were added to the unregistered HDR-BT DVH parameters. (ii) Distribution-adding: the parameters were extracted after the EBRT doses were 3D-summed with the registered HDR-BT doses. Resulting differences between the parameters were investigated. Results: The D0.1cc, D1cc and D2cc from parameter-adding were 21.3% (P < 0.001), 6.3% (P < 0.001) and 3.5% (P < 0.001) smaller than those from distribution-adding. The D10cc was 2.2% (P=0.015) larger for distribution-adding. Conclusion: Distribution-adding was confounded by unsystematic inter/intra-observer rectum-contouring errors and registration accuracy near the anterior rectal wall. Consequently, clinical use of distribution-adding to assess rectal doses requires careful contour and registration evaluation.]]> Thu 28 Oct 2021 13:04:40 AEDT ]]> Should brachytherapy be added to external beam radiotherapy for prostate cancer? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47327 Thu 02 May 2024 15:29:57 AEST ]]> Methodology for commissioning a brachytherapy treatment planning system in the era of 3D planning https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9491 Sat 24 Mar 2018 08:35:37 AEDT ]]> Lessons learned from a HDR brachytherapy well ionisation chamber calibration error https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12302 Sat 24 Mar 2018 08:11:38 AEDT ]]> Dosimetric comparison of optimization methods for multichannel intracavitary brachytherapy for superficial vaginal tumors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19994 Sat 24 Mar 2018 07:50:48 AEDT ]]> Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52813 Fri 27 Oct 2023 17:01:02 AEDT ]]> Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52691 Fri 20 Oct 2023 15:54:55 AEDT ]]> Impact of High-Dose-Rate Brachytherapy Training via Telehealth in Low- and Middle-Income Countries. https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41560 Fri 05 Aug 2022 14:30:40 AEST ]]>